Teva (TEVA) CEO Issues FY12 EPS, Sales Outlook
Speaking at a 2012 Business Outlook Conference Call, Teva's (Nasdaq: TEVA) CEO Shlomo Yanai is offering some guidance: sees FY12 EPS of $5.48-$5.68, which compares to the Street estimate of $5.67, on sales of about $22 billion, vs. the consensus of $21.97 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva and Immuneering Announce Teva’s Purchase of 51% Equity Share of Genomic-Analysis Company
- Teva Pharma (TEVA) Secures $33.75B Financing Commitment Relating to Pending Acquisition of Allergan's Generic Business
- Caesarstone Sdot-Yam (CSTE) Tops Q2 EPS by 3c; Updates FY15 Outlook
Create E-mail Alert Related CategoriesGuidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!